Entacapone and Prostate Cancer Risk in Patients With Parkinson's Disease

The association between Parkinson's disease (PD) and prostate cancer, both common in elderly men, is disputable. In the STRIDE‐PD study, prostate cancer developed in 9 patients (3.7%) receiving levodopa/carbidopa with entacapone, a catechol‐O‐methyltransferase inhibitor, versus 2 cases (0.9%) without entacapone. The current pharmacoepidemiological study aimed to determine whether entacapone increases prostate cancer incidence or mortality in PD patients and whether cumulative exposure affects these rates.

[1]  Piu Chan,et al.  Epidemiology of Parkinson's disease , 2016 .

[2]  J. Jankovic,et al.  The role of FUS gene variants in neurodegenerative diseases , 2014, Nature Reviews Neurology.

[3]  A. Rajput,et al.  Identification of FUS p.R377W in essential tremor , 2014, European journal of neurology.

[4]  E. Tolosa,et al.  Fused in Sarcoma (FUS) gene mutations are not a frequent cause of essential tremor in Europeans , 2013, Neurobiology of Aging.

[5]  P. Hedera,et al.  FUS in familial essential tremor - the search for common causes is still on. , 2013, Parkinsonism & related disorders.

[6]  R. Uitti,et al.  Investigating the role of FUS exonic variants in essential tremor. , 2013, Parkinsonism & related disorders.

[7]  K. Gao,et al.  Genetic analysis of the fused in sarcoma gene in Chinese Han patients with essential tremor , 2013, Neurobiology of Aging.

[8]  A. Mariotto,et al.  Cancer prevalence in United States, Nordic Countries, Italy, Australia, and France: an analysis of geographic variability , 2013, British Journal of Cancer.

[9]  E. Louis,et al.  Genetic analysis of the FUS/TLS gene in essential tremor , 2013, European journal of neurology.

[10]  S. Pulst,et al.  Shared predispositions of parkinsonism and cancer: a population-based pedigree-linked study. , 2012, Archives of neurology.

[11]  G. Rouleau,et al.  Exome sequencing identifies FUS mutations as a cause of essential tremor. , 2012, American journal of human genetics.

[12]  J. Jankovic,et al.  Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE‐PD study , 2010, Annals of neurology.

[13]  E. Schernhammer,et al.  Parkinson’s disease and cancer risk: a systematic review and meta-analysis , 2010, Cancer Causes & Control.

[14]  M. Brin,et al.  Consensus Statement of the Movement Disorder Society on Tremor , 2008, Movement disorders : official journal of the Movement Disorder Society.

[15]  Niels Keiding,et al.  Using prescription registries to define continuous drug use: how to fill gaps between prescriptions , 2008, Pharmacoepidemiology and drug safety.

[16]  D. Brooks,et al.  Five-year efficacy and safety of levodopa/DDCI and entacapone in patients with Parkinson’s disease , 2008, Journal of Neural Transmission.

[17]  F. Hamdy,et al.  Combination of polymorphisms from genes related to estrogen metabolism and risk of prostate cancers: the hidden face of estrogens. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  J. Buring,et al.  A Prospective Cohort Study of Cancer Incidence Following the Diagnosis of Parkinson's Disease , 2007, Cancer Epidemiology Biomarkers & Prevention.

[19]  J. Cerhan,et al.  Evaluation of Genetic Variations in the Androgen and Estrogen Metabolic Pathways as Risk Factors for Sporadic and Familial Prostate Cancer , 2007, Cancer Epidemiology Biomarkers & Prevention.

[20]  M. Breteler,et al.  Epidemiology of Parkinson's disease , 2006, The Lancet Neurology.

[21]  D. Pookot,et al.  Catechol-O-methyltransferase Gene Polymorphisms in Benign Prostatic Hyperplasia and Sporadic Prostate Cancer , 2006, Cancer Epidemiology Biomarkers & Prevention.

[22]  J. Olsen,et al.  Atypical cancer pattern in patients with Parkinson's disease , 2004, British Journal of Cancer.

[23]  Kazuto Ito,et al.  Genetic polymorphisms of estrogen receptor alpha, CYP19, catechol‐O‐methyltransferase are associated with familial prostate carcinoma risk in a Japanese population , 2003, Cancer.

[24]  J. Yager,et al.  Characterization of human soluble high and low activity catechol-O-methyltransferase catalyzed catechol estrogen methylation. , 2002, Pharmacogenetics.

[25]  E. Cavalieri,et al.  Catechol estrogen metabolites and conjugates in different regions of the prostate of Noble rats treated with 4-hydroxyestradiol: implications for estrogen-induced initiation of prostate cancer. , 2002, Carcinogenesis.

[26]  D. Albanes,et al.  The Finnish Cancer Registry as Follow-Up Source of a Large Trial Cohort , 2002, Acta oncologica.

[27]  H Helenius,et al.  Changing epidemiology of Parkinson’s disease in southwestern Finland , 1999, Neurology.

[28]  J. Larsen,et al.  Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations , 1998, Neurology.

[29]  E. Louis,et al.  How common is the most common adult movement disorder? Estimates of the prevalence of essential tremor throughout the world , 1998, Movement disorders : official journal of the Movement Disorder Society.

[30]  Ting Liu,et al.  No association between COMT Val158Met polymorphism and prostate cancer risk: a meta-analysis. , 2013, Genetic testing and molecular biomarkers.

[31]  E. Katunina,et al.  [Epidemiology of Parkinson's disease]. , 2013, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

[32]  C. Wider,et al.  Genetics of essential tremor. , 2012, Parkinsonism & related disorders.

[33]  A Penttilä,et al.  The validity of death certificates: routine validation of death certification and its effects on mortality statistics. , 2001, Forensic science international.

[34]  M. Lehtonen,et al.  Data quality and quality control of a population-based cancer registry. Experience in Finland. , 1994, Acta oncologica.

[35]  E. Pukkala,et al.  DATA QUALITY AND QUALITY CONTROL OF A POPULATION-BASED CANCER REGISTRY , 1994 .